***Background.*** Rifampin is widely utilized in treatment of prosthetic joint infections (PJI) with retained hardware caused by Staphylococcal species. However, there is little data regarding clinical outcomes.

***Methods.*** We conducted a retrospective cohort study of patients with coagulase-negative Staphylococcus (CoNS), methicillin-sensitive (MSSA) and -resistant *Staphylococcus aureus* (MRSA) PJI who were treated with adjunctive rifampin therapy after admission to a large tertiary care hospital from July 2005 to June 2010. The epidemiology, clinical outcomes, and risk factors for failure were examined. Treatment success was defined as no further readmissions for PJI within 1 year of the index hospitalization.

***Results.*** A total of 237 patients with MRSA (56), MSSA (69), or CoNS (112) PJI were identified during the study period. Sixty-eight patients (29%) were discharged with rifampin combination therapy. Amongst patients treated with rifampin, MSSA was isolated in 30% and MRSA isolated in 25%. Partial exchange and debridement and implant retention (DAIR) was completed in 63% of all patients. Vancomycin was the most commonly prescribed IV antibiotic (48, 71%), followed by oxacillin (9, 13%). Concurrent therapy with daptomycin (2, 2.9%) or ceftriaxone (4, 5.9%) was rarely used. Antibiotic duration averaged 51 days (range 30-106, ± 14.6). Abnormal laboratories were common (53, 78%); however, only 18 (26.5%) required a change in antibiotic therapy. The most common side effect necessitating change was rash (9, 13.2%). Significant drug-drug interactions (1) and liver toxicity (2) were rare. Three patients (4%) were lost to follow up. Complications of antibiotic use caused 9% of all readmissions and 25% of the cohort was readmitted for infection (16, 25%). Rifampin use was not associated with decreased readmission for infection (MSSA, p = 0.4; MRSA p = 0.5; CoNS, p = 0.7).

***Conclusion.*** Rifampin has been utilized as adjunctive treatment of staphylococcal PJI in cases of retained hardware. Although well tolerated in the study population, rifampin did not reduce the risk for PJI-related readmission compared to those who did not receive rifampin.
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